Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference
Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.
Adjuvant Ribociclib May Be ‘Promising’ in HR+/HER2– Breast Cancer
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Co–Editor-in-Chief Introduction: Priorities and New Directions
Neil M. Iyengar, MD, gives new directions and ideas as he begins his new position as co–editor-in-chief of ONCOLOGY.
Increased Body Mass Index Shows a Link to Breast Cancer
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
Evolving Landscape of HR+ Metastatic Breast Cancer Management
Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Other Targets in HR+ Breast Cancer: PARP Inhibition and Immune Checkpoint Inhibitors
Expert panelists consider the appropriate use of PARP and immune checkpoint inhibitors, respectively, in the setting of HR+ metastatic breast cancer.
Potential for Targeting Trop-2 in HR+ Metastatic Breast Cancer
A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.
Considering HER2-Directed Therapy in HER2-Low Metastatic Breast Cancer
Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.
Novel Treatment Modalities Under Investigation in HR+ Metastatic Breast Cancer
After briefly addressing resistance to endocrine therapy, expert panelists broadly review novel treatment modalities in the setting of HR+ metastatic breast cancer.
Patient Scenario 2: A Case of Relapsed HR+ Metastatic Breast Cancer
Expert perspectives review a case of relapsed HR+ metastatic breast cancer and consider treatment options available in the second line and beyond.
HR+ Breast Cancer: Factors in Selecting First-Line Therapy for Metastatic Disease
Highlights from key clinical data informing the selection of targeted therapy in particular subsets of patients with HR+ breast cancer.
Role of CDK4/6 Inhibitors as First-Line Therapy for Metastatic HR+ Breast Cancer
Comprehensive insight to the selection of CDK4/6 inhibitors as first-line therapy for patients with metastatic HR+ breast cancer, followed by a brief review of available endocrine partners.
Patient Scenario 1: A Case of Stage II HR+ Breast Cancer
Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.
Future Directions for the Management of HER2+ mBC
Neil Iyengar, MD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Vijayakrishna Gadi, MD, PhD, share clinical pearls for the evolving treatment landscape of HER+ metastatic breast cancer.
Patient Case: 63-Year-Old Woman With HER2+/HR- mBC
Vijayakrishna Gadi, MD, PhD, presents the case of a 63-year-old woman with grade 3 HER+/HR- metastatic breast cancer.
HER2+ Breast Cancer: Optimizing Quality of Life
Breast cancer experts discuss the importance of patient quality of life when considering treatment recommendations for HER2+ breast cancer.
Screening and Monitoring Visceral Disease in HER2+ BC
Claudine Isaacs, MD, comments on the follow-up and monitoring for a patient similar to the case presentation with HER2+ breast cancer.
Patient Case: 50-Year-Old Woman With HER2+/HR- Breast Cancer
Experts in breast cancer discuss the management of visceral metastases in HER2+ breast cancer, and Vijayakrishna Gadi, MD, PhD, presents the case of a 50-year-old woman with HER+/HR- breast cancer.
Treatment of HER2+ Breast Cancer and Brain Metastases
Vijayakrishna Gadi, MD, PhD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Neil Iyengar, MD, share their approach to treating patients with HER+ breast cancer who have brain metastases.
Updates From ASCO 2021 for HER2+ Breast Cancer
Breast cancer experts review unmet needs in the management of HER2+ metastatic breast cancer and updates from the 2021 ASCO virtual meeting.
Standard of Care for HER2+ Metastatic Breast Cancer
Neil Iyengar, MD, leads the discussion on the current standard of care and the sequencing of therapy for HER2+ metastatic breast cancer.
The Evolving Space of HER2+ Breast Cancer
Key opinion leaders discuss recent advancements and future directions in the HER2+ breast cancer space.
Management of ILD in HER2+ BC
Expert panelists react to polling questions and give their input on the management both symptomatic and asymptomatic interstitial lung disease in HER2+ breast cancer, also touching on this impact in the era of COVID-19.
Monitoring Symptoms of ILD in HER2+ Breast Cancer
Experts discuss the careful monitoring of potential interstitial lung disease symptoms, how they proceed if symptoms progress, and how they handle this in patients who are asymptomatic.
Screening and Recognition of ILD in HER2+ BC
Experts in breast cancer respond to polling questions surrounding the recognition of pneumonitis and interstitial lung disease.
HER2+ BC: Considerations for Sequencing Treatment
A panel of experts weighs in the challenges of optimally sequencing therapy for patients with HER2+ breast cancer.
Decision Making in Selecting Treatment in HER2+ BC
Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.
The Role of Prophylactic Therapy in HER2+ BC
Key opinion leaders explore the appropriateness of prophylactic therapy for brain metastases and share their thoughts on best practices.
Management Approaches for Patients with HER2+ BC at Risk for Brain Metastases
An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.
Patient Case: A 37-Year-Old Woman With HER2+/HR- Breast Cancer
Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.